title: BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements.
abstract: The Biopharmaceutics Classification System (BCS), based on aqueous solubility and intestinal permeability, has enjoyed wide use since 1995 as a mechanism for waiving in vivo bioavailability and bioequivalence studies. In 2000, the US-FDA was the first regulatory agency to publish guidance for industry describing how to meet criteria for requesting a waiver of in vivo bioavailability and bioequivalence studies for highly soluble, highly permeable (BCS Class I) drugs. Subsequently, the World Health Organization (WHO) and European Medicines Agency (EMA) published guidelines recommending how to obtain BCS biowaivers for BCS Class III drugs (high solubility, low permeability), in addition to Class I drugs. In 2015, the US-FDA became better harmonized with the EMA and WHO following publication of two guidances for industry outlining criteria for obtaining BCS biowaivers for both Class I and Class III drugs. A detailed review and comparison of the BCS Class I and Class III criteria currently recommended by the US-FDA, EMA, and WHO revealed good convergence of the three agencies with respect to BCS biowaiver criteria. The comparison also suggested that, by applying the most conservative of the three jurisdictional approaches, it should be possible for a sponsor to design the same set of BCS biowaiver studies in preparing a submission for worldwide filing to satisfy US, European, and emerging market regulators. It is hoped that the availability of BCS Class I and Class III biowaivers in multiple jurisdictions will encourage more sponsors to request waivers of in vivo bioavailability/bioequivalence testing using the BCS approach.
authors.affiliation: Merck Research Laboratories, Rahway, New Jersey, USA. barbara.davit@merck.com.
authors.forename: Barbara M
authors.identifier: 0000-0002-6501-5882
authors.initials: BM
authors.lastname: Davit
authors.affiliation: Rhodes University, Grahamstown, South Africa.
authors.forename: Isadore
authors.initials: I
authors.lastname: Kanfer
authors.affiliation: Apotex Inc., Toronto, Ontario, Canada.
authors.forename: Yu Chung
authors.initials: YC
authors.lastname: Tsang
authors.affiliation: Auvergne University, Clermont-Ferrand, France.
authors.forename: Jean-Michel
authors.initials: JM
authors.lastname: Cardot
mesh_terms: D000818:Animals; D001682:Biological Availability; D001702:Biopharmaceutics / Q000331:legislation & jurisprudence / Q000379:methods*; D017277:Drug Approval / Q000331:legislation & jurisprudence / Q000379:methods*; D005060:Europe; D006801:Humans; D004364:Pharmaceutical Preparations / Q000592:standards*; D012995:Solubility; D013810:Therapeutic Equivalency; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence; D014944:World Health Organization
chemical_list: D004364:Pharmaceutical Preparations
keywords: bioavailability; bioequivalence; biopharmaceutics classification system; in vitro dissolution; regulatory guidance